Team care to help people in supportive housing get hepatitis C treatment
Tests a pharmacist, doctor and navigator care team for hepatitis C in supportive housing.
Key facts
- Who runs it
- University of Washington
- Where
- Seattle, United StatesSee the site
- Trial code
- Registry title
- Hepatitis C Pharmacist, Physician, Patient Navigator Collaborative Care Model in Permanent Supportive Housing
- Status
- Recruiting
- People taking part
- 444 people, planned
- Started
- 1 Jun 2026
- Expected to end
- Jun 2029
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- PPP-CCM
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a positive hepatitis C (HCV) test who live in one of DESC's permanent supportive housing buildings in Seattle and King County. It tests a care model where pharmacists, physicians and patient navigators work together.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Hepatitis C (HCV) infection with a positive test on record
- Earlier treatment
- People already taking medicine for HCV at the start of the study cannot join.
- Biomarker or test result
- Positive HCV test on record (screening antibody test or viral load test)
Main reasons for not taking part
- Currently taking medicine to treat HCV
- Memory or thinking problems that prevent giving informed consent
- In prison now or soon to be
- Planning to leave the Seattle area within 24 months
- Not English speaking, or behaviour that research staff judge a safety concern
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adult ≥18 years of age
- Currently a resident at one of DESC's PSH buildings at the time of study enrollment
- Positive HCV test documented (screening antibody test or viral load test)
- Provides release of information (ROI) to access community pharmacy electronic medical records (EHR) and/or other HCV treatment providers for information on HCV care during the study period between baseline visit and 24-month visit
Who cannot take part
- Taking medications to treat HCV at the start of the study
- Cognitive impairment (acute or chronic) resulting in inability to provide informed consent
- Currently or impending incarceration
- People who plan to leave the Seattle area within 24 months
- Not English speaking
- Behavioral risk posing safety concerns per discretion of research staff
Where in United States
- Harborview Medical CenterSeattle, United StatesContact: Judith I Tsui, MD MPHTaking people
About the trial
What the trial wants to find out
The objective of this study is to extend our prior research by conducting a pragmatic implementation trial using a parallel-group, cluster randomized design to evaluate the PPP-CCM's ability to improve access to DAAs for HCV within a network of permanent supportive housing (PSH) buildings in Seattle and King County. The study will implement PPP-CCM to 16 housing buildings, randomizing half to receive PPP-CCM (intervention) versus usual care (UC) for 12-months, after which all buildings will have access to PPP-CCM. All buildings will have access to point-of-care HCV screening for the first 6 months of the study. Study outcome data will be collected through a longitudinal cohort-study of persons who screened positive for HCV which will conduct surveys and review of medical records at baseline, 12- and 24-months.
The 2 groups in the trial
- Treatment-as-usual (TAU)No study treatment, for comparison
TAU will be usual care provided by the permanent supportive housing buildings.
- PPP-CCMTreatment being tested
The intervention is a "Pharmacist, Physician, Patient Navigator Collaborative Care Model" (PPP-CCM) approach for expanding access to direct-acting antivirals (DAAs) for HCV. This task-shifting, collaborative care model leverages pharmacists to deliver medications-namely DAAs for HCV, as well as pre-exposure prophylaxis (PrEP) for HIV and naloxone for overdose prevention-to PWUD through "Collaborative Practice Agreements" (CPAs) with physicians in conjunction with support from patient navigators.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Hybrid Implementation-Effectiveness Study of the Pharmacist, Physician, and Patient Navigator Collaborative Care Model (PPP-CCM) to Cure Hepatitis C Among Persons Who Use Drugs With Housing Insecurity
- Plain-language title
- Team care to help people in supportive housing get hepatitis C treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 12 November 2026